Sheena N. Smith

Sheena N. Smith

Auto-generated profile, based on publicly available information

Sheena N. Smith

Department of Biochemistry, University of Zurich, 8057 Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DHDaniel T. Harris
Daniel T. Harris
MHMarlies V. Hager
Marlies V. Hager
SSSheena N. Smith
Sheena N. Smith
QCQi Cai
Qi Cai
JSJennifer D. Stone
Jennifer D. Stone
DKDavid M. Kranz
David M. Kranz
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic cancers. Two types of receptor systems have been used to redirect the activity of T cells, normal heterodimeric TCRs or synthetic chimeric Ag receptors (CARs). TCRs recognize peptide-HLA complexes whereas CARs typically use an Ab-derived single-chain fragments variable that recognizes cancer-associated cell-surface Ags. Although both receptors mediate diverse effector functions, a quantitative comparison of the sensitivity and signaling capacity of TCRs and CARs has been limited due to their differences in affinities and ligands. In this study we describe their direct comparison by using TCRs that could be formatted either as conventional αβ heterodimers, or as single-chain fragments variable constructs linked to CD3ζ and CD28 signaling domains or to CD3ζ alone. Two high-affinity TCRs (KD values of ∼50 and 250 nM) against MART1/HLA-A2 or WT1/HLA-A2 were used, allowing MART1 or WT1 peptide titrations to easily assess the impact of Ag density. Although CARs were expressed at higher surface levels than TCRs, they were 10–100-fold less sensitive, even in the absence of the CD8 coreceptor. Mathematical modeling demonstrated that lower CAR sensitivity could be attributed to less efficient signaling kinetics. Furthermore, reduced cytokine secretion observed at high Ag density for both TCRs and CARs suggested a role for negative regulators in both systems. Interestingly, at high Ag density, CARs also mediated greater maximal release of some cytokines, such as IL-2 and IL-6. These results have implications for the next-generation design of receptors used in adoptive T cell therapies.

13 July 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
NKNicole Kirchhammer
Nicole Kirchhammer
MTMarcel P. Trefny
Marcel P. Trefny
MNMarina Natoli
Marina Natoli
DBDominik Brücher
Dominik Brücher
SSSheena N. Smith
Sheena N. Smith
AZAlfred Zippelius
Alfred Zippelius
T cell–directed cancer immunotherapy often fails to generate lasting tumor control. Harnessing additional effectors of the immune response against tumors may strengthen the clinical benefit of immunotherapies. Here, we demonstrate that therapeutic targeting of the interferon-γ (IFN-γ)–interleukin-12 (IL-12) pathway relies on the ability of a population of natural killer (NK) cells with tissue-resident traits to orchestrate an antitumor microenvironment. In particular, we used an engineered adenoviral platform as a tool for intratumoral IL-12 immunotherapy (AdV5–IL-12) to generate adaptive antitumor immunity. Mechanistically, we demonstrate that AdV5–IL-12 is capable of inducing the expression of CC-chemokine ligand 5 (CCL5) in CD49a + NK cells both in tumor mouse models and tumor specimens from patients with cancer. AdV5–IL-12 imposed CCL5-induced type I conventional dendritic cell (cDC1) infiltration and thus increased DC-CD8 T cell interactions. A similar observation was made for other IFN-γ–inducing therapies such as Programmed cell death 1 (PD-1) blockade. Conversely, failure to respond to IL-12 and PD-1 blockade in tumor models with low CD49a + CXCR6 + NK cell infiltration could be overcome by intratumoral delivery of CCL5. Thus, therapeutic efficacy depends on the abundance of NK cells with tissue-resident traits and, specifically, their capacity to produce the DC chemoattractant CCL5. Our findings reveal a barrier for T cell–focused therapies and offer mechanistic insights into how T cell–NK cell–DC cross-talk can be enhanced to promote antitumor immunity and overcome resistance.

1 January 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TSTerry Sasser
Terry Sasser
QQQuan-Sheng Qiu
Quan-Sheng Qiu
SKSurya Karunakaran
Surya Karunakaran
MPMark Padolina
Mark Padolina
ARAnna Reyes
Anna Reyes
RFRutilio A. Fratti
Rutilio A. Fratti
Vacuole homotypic fusion requires a group of regulatory lipids that includes diacylglycerol, a fusogenic lipid that is produced through multiple metabolic pathways including the dephosphorylation of phosphatidic acid (PA). Here we examined the relationship between membrane fusion and PA phosphatase activity. Pah1p is the single yeast homologue of the Lipin family of PA phosphatases. Deletion of PAH1 was sufficient to cause marked vacuole fragmentation and abolish vacuole fusion. The function of Pah1p solely depended on its phosphatase activity as complementation studies showed that wild type Pah1p restored fusion, whereas the phosphatase dead mutant Pah1p(D398E) had no effect. We discovered that the lack of PA phosphatase activity blocked fusion by inhibiting the binding of SNAREs to Sec18p, an N-ethylmaleimide-sensitive factor homologue responsible for priming inactive cis-SNARE complexes. In addition, pah1Δ vacuoles were devoid of the late endosome/vacuolar Rab Ypt7p, the phosphatidylinositol 3-kinase Vps34p, and Vps39p, a subunit of the HOPS (homotypic fusion and vacuole protein sorting) tethering complex, all of which are required for vacuole fusion. The lack of Vps34p resulted in the absence of phosphatidylinositol 3-phosphate, a lipid required for SNARE activity and vacuole fusion. These findings demonstrate that Pah1p and PA phosphatase activity are critical for vacuole homeostasis and fusion.

7 November 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSheena N. Smith
Sheena N. Smith
YWYuhang Wang
Yuhang Wang
JBJavier L. Baylon
Javier L. Baylon
NSNishant K. Singh
Nishant K. Singh
BBBrian M. Baker
Brian M. Baker
DKDavid M. Kranz
David M. Kranz
Binding of a T-cell receptor (TCR) to a peptide/major histocompatibility complex is the key interaction involved in antigen specificity of T cells. The recognition involves up to six complementarity determining regions (CDR) of the TCR. Efforts to examine the structural basis of these interactions and to exploit them in adoptive T-cell therapies has required the isolation of specific T-cell clones and their clonotypic TCRs. Here we describe a strategy using in vitro-directed evolution of a single TCR to change its peptide specificity, thereby avoiding the need to isolate T-cell clones. The human TCR A6, which recognizes the viral peptide Tax/HLA-A2, was converted to TCR variants that recognized the cancer peptide MART1/HLA-A2. Mutational studies and molecular dynamics simulations identified CDR residues that were predicted to be important in the specificity switch. Thus, in vitro engineering strategies alone can be used to discover TCRs with desired specificities.

17 May 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SSSheena N. Smith
Sheena N. Smith
RSRajib Schubert
Rajib Schubert
BSBranko Simic
Branko Simic
DBDominik Brücher
Dominik Brücher
MSMarkus Schmid
Markus Schmid
APAndreas Plückthun
Andreas Plückthun
Significance: A challenge in cancer therapy is delivering high, consistent levels of therapeutics to tumors. Protein-based therapeutics (e.g., antibodies) are typically delivered intravenously and require multiple doses to get sufficient levels to traffic into tumors to exert an effect. Yet healthy tissues are also exposed to similar drug levels, which can lead to significant side effects. This study uses sophisticated three-dimensional imaging of transparent tumors to characterize a versatile gene therapy platform using adenovirus that solves this problem by producing drugs directly in the tumor. This approach increases the tumor-to-bloodstream level of a model antibody 1,800-fold in comparison to direct administration. Thus, this system could allow for the local production of highly potent drugs with greatly reduced risk of systemic toxicities.

26 May 2016 in Structure
Verified
Journal Article
Open access
PDF file
DHDaniel T. Harris
Daniel T. Harris
NSNishant K. Singh
Nishant K. Singh
QCQi Cai
Qi Cai
SSSheena N. Smith
Sheena N. Smith
CKCraig W. Vander Kooi
Craig W. Vander Kooi
BBBrian M. Baker
Brian M. Baker
• Switching TCR specificity via in vitro evolution leads to an unusual binding mode • The engineered TCR still signals in an antigen-specific manner • Disruption of canonical TCR-MHC interactions catalyzes the specificity switch • Further contributions to the switch are distributed throughout the interface